Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637417 | 0.87 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3647136 | 0.84 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3642761 | 0.83 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3642020 | 0.81 | GRIA1 (0.44) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3645817 | 0.81 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3643803 | 0.80 | BRD4 (0.58) | BRD4 | |
| SCHEMBL3642384 | 0.79 | HTR7 (0.45) | FFAR1BRD4GRIA1CACNG8DRD2 | |
| SCHEMBL3976784 | 0.79 | MKNK1 (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3645250 | 0.77 | PDPK1 (0.53) | FFAR1BRD4GRIA1CACNG8DRD2 | |
| SCHEMBL3975536 | 0.76 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232307-B2 | Indane-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-07-31 | — | — | US | claimed |
| US-20110053980-A1 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| EP-2173712-A2 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-04-14 | — | — | EP | claimed |
| WO-2009003719-A2 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-08 | — | — | WO | claimed |
| EP-2011786-A1 | Indane-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-07 | — | — | EP | claimed |
| US-8232307-B2 | Indane-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-07-31 | — | — | US | disclosed |
| US-20110053980-A1 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-2173712-A2 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009003719-A2 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-08 | — | — | WO | disclosed |
| EP-2011786-A1 | Indane-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053980-A1 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | INMT, IDO1, PNMT | ADRA2A 32/4885ADRA2B 70/4885ADRA2C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.